Kaul, R., McGeer, A., Norrby-Teglund, A., Kotb, M., Schwartz, B., O’Rourke, K., Talbot, J. and Low, D.E. (1999) The Canadian Streptococcal Study Group; Intravenous Immunoglobulin Therapy for Streptococcal Toxic Shock Syndrome—A Comparative Observational Study. Clinical Infectious Diseases, 28, 800-807.
https://doi.org/10.1086/515199

has been cited by the following article:

• TITLE: Necrotizing Fasciitis in the Puerperium of a Woman with Complement Deficiency: Case Report and Review Literature

  AUTHORS: Janete Vettorazzi, Edimárlei Gonsales Valério, Gustavo Adolpho Moreira Faulhaber, Amanda Vilaverde Perez, Mariana Sbaraini, Daniela Vanessa Vettori

  KEYWORDS: Pregnancy, Immunodeficiency, C4 Factor, C4 Deficiency, Necrotizing Fasciitis, Puerperal Infection

  JOURNAL NAME: Open Journal of Obstetrics and Gynecology, Vol.8 No.12, October 26, 2018

  ABSTRACT: Complement deficiencies are uncommon types of primary immunodeficiency. Necrotizing fasciitis is a rare complication in pregnancy characterized by soft tissue invasion and necrosis of the subcutaneous and other adjacent tissues, leading to high mortality rates. We report a case of a 29-year-old pregnant woman with functional deficiency of the C4 complement component and short uterine cervix. Admitted at the hospital with preterm labor, she received multiple doses of immunoglobulin. After 8 weeks, she had a premature membrane rupture, and due to pelvic presentation she had a cesarean. The patient presented multiple obstetric complications, such as operative wound infection, endometritis, sepsis, necrotizing fasciitis and pelvic septic thrombophlebitis. She underwent multiple antimicrobial schemes, a hysterectomy and 4 extensive debridements of the abdominal wall because of significant necrosis. She stayed at the hospital for 101 days (32 of those in ICU in immediate postpartum). 41 days after cesarean, patient was discharged in good conditions. Our case emphasizes individual handling and high multiple doses of immunoglobulin for favorable outcome of the case.